



Abbott Laboratories (Pakistan) Limited
City Office:
11th & 12th Floors, Ocean Tower, G-3,
Block-9, Main Clifton Road,
Karachi, Sindh 75600
P.O. Box No. 13841, Karachi
Tel: +92-21-38709369, +92-21-32799018

Abbott Laboratories (Pakistan) Limited
Registered Office:
Opp. Radio Pakistan Transmission Centre,
Hyderabad Road, Landhi, Karachi-75120
P.O. Box 7229 Karachi 74400
Tel: +92-21-111-Abbott (111-222-688)

March 16th, 2026

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi

Subject: Financial Results for year ended December 31st, 2025

Dear Sir,

We have to inform you that the Board of Directors of our Company in their meeting held on Monday, March 16th, 2026, at 11:45 a.m. at Karachi recommended the following:

CASH DIVIDEND


A Final Cash Dividend for the year ended December 31st, 2025, at Rs. 40 per share (i.e. 400%).

The financial results of the Company are as follows:-

	<u>2025</u>	<u>2024</u>
	<u>(Rupees 000's)</u>	
Sales net	75,397,732	68,177,197
Cost of sales	<u>(48,945,569)</u>	<u>(48,439,489)</u>
Gross Profit	26,452,163	19,737,708
Selling and distribution expenses	<u>(11,085,579)</u>	<u>(9,302,303)</u>
Administrative expenses	<u>(1,363,604)</u>	<u>(1,169,133)</u>
Other charges	<u>(1,587,644)</u>	<u>(838,381)</u>
Other income	1,159,880	723,242
	<u>(12,876,947)</u>	<u>(10,586,575)</u>
	13,575,216	9,151,133
Finance costs	<u>(75,659)</u>	<u>(23,614)</u>
Profit before minimum tax differential, final taxes and income tax	13,499,557	9,127,519
Minimum tax differential	-	<u>(105,530)</u>
Profit before income tax	13,499,557	9,021,989
Income tax	<u>(5,533,057)</u>	<u>(3,787,756)</u>
Profit for the year	<u>7,966,500</u>	<u>5,234,233</u>
	<u>(Rupees)</u>	
Earnings per share - basic/diluted	<u>81.37</u>	<u>53.46</u>

The Annual General Meeting of the Company will be held on Thursday, April 23rd, 2026, at 11:00 a.m at ICAP Auditorium, Chartered Accountants Avenue, Clifton, Karachi.

The above entitlement will be paid to the Shareholders whose names will appear in the Register of Members on Wednesday, April 15th, 2026.



- 2 -

The Share Transfer Books of the Company will be closed from Thursday, April 16th, 2026 to Thursday, April 23rd, 2026 (both days inclusive). Transfers received by our Registrar FAMCO Share Registration Services (Pvt) Limited, 8-F, next to Hotel Faran, Nursery, Block-6 P.E.C.H.S Shahrah-e-Faisal, Karachi at the close of business on Wednesday, April 15th, 2026 will be treated in time for the purpose of payment of dividend to the transferees.

The Annual Report of the Company will be transmitted through PUCARS atleast 21 days before holding of Annual General Meeting.

**Yours faithfully,
ABBOTT LABORATORIES (PAKISTAN) LIMITED**

**SYED ANIS AHMED
CHIEF EXECUTIVE &
MANAGING DIRECTOR**

ABBOTT LABORATORIES (PAKISTAN) LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT DECEMBER 31, 2025

	Note	2025 (Rupees '000)	2024		Note	2025 (Rupees '000)	2024
<u>EQUITY AND LIABILITIES</u>				<u>ASSETS</u>			
SHARE CAPITAL AND RESERVES				NON-CURRENT ASSETS			
Authorised capital	3	<u>2,000,000</u>	<u>2,000,000</u>	Property, plant and equipment	11	15,635,851	14,252,797
Issued, subscribed and paid-up capital	4	979,003	979,003	Intangible assets	12	831	1,250
Reserves - capital		2,073,901	1,750,481	Long-term loans and advances	13	141,175	114,226
- revenue		28,572,553	20,995,152	Long-term deposits		32,628	7,513
Total equity		<u>31,625,457</u>	<u>23,724,636</u>	Long-term prepayments		12,395	13,710
NON-CURRENT LIABILITIES				Total non-current assets			
Deferred taxation - net	5	989,965	1,052,587			<u>15,822,880</u>	<u>14,389,496</u>
Staff retirement benefits	6	494,943	1,184,179	CURRENT ASSETS			
Lease liabilities	7	329,677	29,545	Stores and spares	14	669,690	529,619
Total non-current liabilities		<u>1,814,585</u>	<u>2,266,311</u>	Stock-in-trade	15	12,447,838	10,694,515
CURRENT LIABILITIES				Trade debts	16	2,820,530	2,982,679
Trade and other payables	8	12,198,722	10,951,662	Loans and advances	17	399,086	938,021
Unclaimed dividends		71,155	63,715	Trade deposits and short-term prepayments	18	313,552	283,813
Taxation - net		246,958	-	Other receivables	19	1,005,069	1,182,530
Current portion of lease liabilities	7	158,301	22,683	Taxation - net		-	468,136
Provisions	9	701,018	622,151	Cash and cash equivalents	20	13,337,551	6,182,349
Total current liabilities		<u>13,376,154</u>	<u>11,660,211</u>	Total current assets		<u>30,993,316</u>	<u>23,261,662</u>
CONTINGENCIES AND COMMITMENTS							
	10						
TOTAL EQUITY AND LIABILITIES		<u>46,816,196</u>	<u>37,651,158</u>	TOTAL ASSETS		<u>46,816,196</u>	<u>37,651,158</u>

The annexed notes 1 to 43 form an integral part of these financial statements.

Chief Executive Officer

Director

Chief Financial Officer

ABBOTT LABORATORIES (PAKISTAN) LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED DECEMBER 31, 2025

	Reserves					Total	Total equity
	Capital reserves		Revenue reserves				
	Reserve arising on merger	Share based compensation reserve	General reserve	Un-appropriated profit			
	(Rupees '000)						
Balance as at January 01, 2024	979,003	46,097	1,391,065	5,338,422	10,482,759	17,258,343	18,237,346
Employee benefit cost under IFRS 2 - 'Share-based payments'	-	-	313,319	-	-	313,319	313,319
Total comprehensive income for the year ended December 31, 2024							
Profit for the year	-	-	-	-	5,234,233	5,234,233	5,234,233
Other comprehensive loss for the year - net of tax	-	-	-	-	(60,262)	(60,262)	(60,262)
Total comprehensive income for the year	-	-	-	-	5,173,971	5,173,971	5,173,971
Balance as at December 31, 2024	979,003	46,097	1,704,384	5,338,422	15,656,730	22,745,633	23,724,636
Balance as at January 01, 2025	979,003	46,097	1,704,384	5,338,422	15,656,730	22,745,633	23,724,636
Final dividend for the year ended December 31, 2024 @ Rs 10.0 per share					(979,003)	(979,003)	(979,003)
Employee benefit cost under IFRS 2 - 'Share-based payments'	-	-	323,420	-	-	323,420	323,420
Total comprehensive income for the year ended December 31, 2025							
Profit for the year	-	-	-	-	7,966,500	7,966,500	7,966,500
Other comprehensive income for the year - net of tax	-	-	-	-	589,904	589,904	589,904
Total comprehensive income for the year	-	-	-	-	8,556,404	8,556,404	8,556,404
Balance as at December 31, 2025	979,003	46,097	2,027,804	5,338,422	23,234,131	30,646,454	31,625,457

The annexed notes 1 to 43 form an integral part of these financial statements

Chief Executive Officer

Director

Chief Financial Officer

ABBOTT LABORATORIES (PAKISTAN) LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED DECEMBER 31, 2025

	2025	2024	
Note (Rupees '000)	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	30	16,074,607	8,356,459
Income tax paid		(5,019,980)	(3,325,706)
Minimum tax differential paid		-	(105,530)
Long-term loans and advances		(26,949)	(18,803)
Long term deposits		(25,115)	-
Long-term prepayments		1,315	(10,283)
Contributions to staff retirement benefit funds	6.7	(342,438)	(300,648)
Net movement in provisions		78,867	78,574
Net cash generated from operating activities		<u>10,740,307</u>	<u>4,674,063</u>
CASH FLOWS FROM INVESTING ACTIVITIES			
Additions to property, plant and equipment		(3,299,028)	(3,022,082)
Sale proceeds from disposal of operating fixed assets	11.5	280,189	181,547
Interest income on Term Deposit Receipts and saving accounts		535,097	472,177
Net cash used in investing activities		(2,483,742)	(2,368,358)
CASH FLOWS FROM FINANCING ACTIVITIES			
Bank charges paid		(9,201)	(11,875)
Interest portion of lease liabilities paid	7.1	(66,458)	(11,739)
Principal portion of lease liabilities paid		(54,141)	(105,990)
Dividends paid	31	(971,563)	(1,030,464)
Net cash used in financing activities		(1,101,363)	(1,160,068)
Net increase in cash and cash equivalents		<u>7,155,202</u>	<u>1,145,637</u>
Cash and cash equivalents at the beginning of the year		6,182,349	5,036,712
Cash and cash equivalents at the end of the year	20	<u><u>13,337,551</u></u>	<u><u>6,182,349</u></u>

The annexed notes 1 to 43 form an integral part of these financial statements.

Chief Executive Officer

Director

Chief Financial Officer